Dr Antonio Galleu graduated in Medicine in 2005 and completed his Haematology training in 2011 at the University of Sassari (Italy) where he was co-investigator of many studies on T-cell Receptor Repertoire in haematological and non-haematological diseases. Since 2010 he has been working in Prof. Dazzi’s group and been investigating the immunosuppressive properties of Mesenchymal Stromal Cells (MSCs) and their applications for the treatment of Graft versus Host Disease (GvHD) and other immuno-mediated diseases. With his collaborators he recently published his work on the role of apoptosis in MSCs as a crucial driver for the final delivery of MSC therapeutic activity, which represents a paradigm shift in the MSC therapeutics. The contribution in the field has been recognised with the prestigious J. Jon van Rood 2018 award for the best paper in the Immunology of Allogeneic Hematopoietic Transplantation in the Cellular Therapy and Immunobiology Working Party 2018. Based on the data obtained he filed a patent application for a functional assay used as biomarker able to predict the clinical activity of MSCs in GvHD patients. In June 2018 he was granted the John Goldman Fellowship for Future Science by Leuka. Current position: Clinical Research Fellow at King’s College London and production scientist for the MSC group at the Cellular Therapy Unit, King’s College Hospital. His core expertise is: GvHD, professional knowledge of GMP regulations (HTA and MHRA) on ATMPs and IMPs, cellular therapy, Immunology/Haematology, molecular biology, cell biology, pre-clinical models of Graft versus Host Disease, liver and peritoneum inflammation.